Editas Medicine
AWARDS
NEWS
The future of Editas Medicine’s EDIT-101 will be determined later in November after a data readout is available. The data could inform the company whether there is a potential commercial path forward.
While worthy advances have recently been made in sickle cell disease, companies such as Graphite Bio, bluebird bio, Vertex Pharmaceuticals and Editas Medicine have loftier ambitions.
Editas is reportedly in “advanced discussions” regarding the sale of its preclinical cancer lineup. The company told BioSpace it has undertaken a strategic review to inform opportunities.
Only weeks after announcing a new chief executive officer and chief medical officer, Editas Medicine reported promising early data for its Phase I/II RUBY trial of EDIT-301 for severe sickle cell disease (SCD).
Five weeks after taking the reins as CEO of CRISPR-focused Editas Medicine, Gilmore O’Neill fulfilled his first task, appointing a new chief medical officer.
Aslan partners with Johns Hopkins and Duke, Editas joins forces with Immatics, Yumanity (soon to be Kineta, Inc.) teams with Janssen, Serotiny & Janssen Biotech and Ginkgo and Novo Nordisk.
U.S. Food and Drug Administration(FDA) has granted Orphan Drug designations to Editas Medicine and Neurocrine Biosciences.
Editas Medicine snagged Rare Pediatric Disease designation for its experimental beta thalassemia gene therapy, while VBL received Fast Track designation for an ofra-vec combination in ovarian cancer.
O’Neill, who has served as chief medical officer at Sarepta Therapeutics since 2018, said he is excited about the potential of Editas’ pipeline.
JOBS
IN THE PRESS